Impact of measurable residual disease in combination with CD19 on postremission therapy choices for adult t(8;21) acute myeloid leukemia in first complete remission.

Xi JiaNaying LiaoSijian YuHuan LiHui LiuHaiyan ZhangJun XuYunqian YaoHan HeGuopan YuQi-Fa LiuYu ZhangPengcheng Shi

Published in: Cancer medicine (2024)

MRD combined with CD19 might optimize PRT choices for adult t(8;21) AML patients in CR1.

Keyphrases